ATRA - Atara Biotherapeutics Inc logo

Atara Biotherapeutics Inc

ATRA

Atara Biotherapeutics develops T-cell immunotherapies for cancer and autoimmune diseases, focusing on treatments like Tab-cel for EBV-related conditions and ATA3219 for B-cell malignancies. It partners with research institutions for collaborative studies.

โš•๏ธ Healthcare NASDAQ Listed 2014 $ USD
$1,000 invested 10 years ago โ†’$25today

Score Overview

1 Year
Score
Net Growth-151.05%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth-94.87%
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score5.0
Net Growth95.09%
Net Trend60%
Net Income Consistencyโ€”
Rev Growth-69.55%
Rev Trend40%
Revenue Consistencyโ€”
10 Years
Scoreโ€”
Net Growth78.89%
Net Trend30%
Net Income Consistency
Rev Growthโ€”
Rev Trend40%
Revenue Consistency
All Time
Scoreโ€”
Net Growth40.41%
Net Trend25%
Net Income Consistency
Rev Growthโ€”
Rev Trend33%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Atara Biotherapeutics Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. ATRA does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-22
$ 9.43โ€”
1 Year2025-10-22
$ 14.63-35.54%
5 Years2021-10-22
$ 400.75-97.65%
10 Years2016-10-21
$ 372.50-97.47%
All Time2014-10-16
$ 266.25-96.46%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 6M-$ 16M$ 9M
2025$ 120M$ 32M$ 8M
2024$ 128M-$ 85M$ 42M
2023$ 8M-$ 276M$ 51M
2022$ 63M-$ 228M$ 242M
2021$ 20M-$ 340M$ 371M
2020$ 3M-$ 306M$ 500M
2019$ 0.00-$ 290M$ 259M
2018$ 0.00-$ 230M$ 309M
2017$ 0.00-$ 119M$ 166M
2016$ 0.00-$ 79M$ 255M
2015$ 0.00-$ 57M$ 320M
IPO2014$ 0.00-$ 28M$ 104M
ATRA - Atara Biotherapeutics Inc logo

Atara Biotherapeutics Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 3M to $ 120M and net income went from -$ 306M to $ 32M. Revenue increased in 2 of those 5 years; net income in 3.

Atara Biotherapeutics Inc currently holds a 5-year HDB Score of 5.0 out of 10. How the HDB Score is calculated.

Membership

Explore ATRA with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,119 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies